Ginkgo partners up with Sensible Biotechnologies to forge mRNA manufacturing platform
Since the successful, global release of mRNA-based Covid-19 vaccines, the mRNA platform has become a top focus for biopharma companies. Ginkgo Bioworks’ latest partnership looks to further tap the mRNA market.
On Monday, Sensible Biotechnologies — a European-based biotech looking to build a cell-based platform to produce mRNA — and Ginkgo announced a partnership to develop such a manufacturing platform. The announcement said most of the mRNA that is used in vaccines and other therapeutic products is produced by in vitro transcription, which is cell-free and uses purified enzymes. The standard forms of mRNA production are limited in how much can be made and need to go through costly purification methods to eliminate byproducts that could cause adverse reactions in patients.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.